International Program Committee

The 2022 Summit International Program & Coordination Committee 

Vanessa EL HARRAR, MD, MPH,

Vice President, Vaccines Business Strategy Lead, @ PPD BIOTECH [Thermo Fisher Group]. Boca Raton, FL, USA. Previously, Dr El Harrar was Director of Therapeutic Research, Office of the Director, NIH: National Institutes of Health, Bethesda, MD, USA

Jessica FOLEY, MS, RAC

Principal Consultant and Founder of Gaia Regulatory Sciences, LLC, CIC Cambridge, MA. Senior regulatory professional, providing strategic due diligence, product development and approval strategies through her consultancy, with a focus on investigational therapies for the treatment of rare and common conditions.

Shahin Gharakhanian, MD, DPH
[Principal & Program Chair]

Co-founder in 2017, Boston-Paris Biotechnology Summit® Principal & Chief Medical Officer Shahin Gharakhanian MD Consulting LLC, CIC: Cambridge Innovation Center Cambridge MA, USA

Silvia Helou, MD

Principal & Executive Consultant, HELOU Consulting LLC, New York Metropolitan Area, NY, USA. Dr Helou has extensive drug development experience in major therapeutic areas including anti-infectives, dermatology, oncology/hematology, and immunology/biologics. She previously held various senior positions at Novartis, Schering-Plough and Scynexis in clinical development.

Frederic Jallat, PhD

Professor & Academic Director, ESCP Paris European Business School, Paris, FRANCE. Campuses: Berlin, London, Madrid, Paris, Turin, and Warsaw. Frederic Jallat, PhD (ESSEC) and New York University is a leading Thought Leader in France/EU in the field of Pharmaceutical & Life Sciences educational strategy.

Brian Malkin, J.D. Law

Partner IP and FDA Practice, MWE: McDermott Will Emery, International Law Firm, Washington DC, USA. Brian Malkin counsels pharmaceutical and biologic clients on Food and Drug Administration (FDA) regulatory matters and intellectual property (IP) law, with an emphasis on patent litigation.

Karine Rossignol, Pharm D

CEO, SMART IMMUNE, developing a T-cell progenitor-based cell therapy platform, Paris, FRANCE. Karine Rossignol is Pharm D/HEC has more than 25 years international experience as leading manager in industry and biomedical research, structuring, scaling up and managing large scale operations.